Segall Bryant & Hamill LLC Trims Position in iRhythm Technologies $IRTC

Segall Bryant & Hamill LLC lowered its position in iRhythm Technologies (NASDAQ:IRTC) by 8.7% in the third quarter, HoldingsChannel reports. The firm owned 125,298 shares of the company’s stock after selling 11,995 shares during the period. Segall Bryant & Hamill LLC’s holdings in iRhythm Technologies were worth $21,550,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IRTC. Root Financial Partners LLC acquired a new position in iRhythm Technologies in the 3rd quarter valued at about $30,000. Smartleaf Asset Management LLC raised its position in shares of iRhythm Technologies by 100.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after buying an additional 99 shares during the period. Optiver Holding B.V. acquired a new position in iRhythm Technologies in the third quarter valued at approximately $35,000. Assetmark Inc. grew its position in iRhythm Technologies by 273.9% in the third quarter. Assetmark Inc. now owns 415 shares of the company’s stock worth $71,000 after acquiring an additional 304 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in iRhythm Technologies during the second quarter worth $72,000.

iRhythm Technologies Stock Down 2.0%

IRTC stock opened at $125.85 on Wednesday. iRhythm Technologies has a 52 week low of $92.52 and a 52 week high of $212.00. The company has a market cap of $4.07 billion, a P/E ratio of -89.89 and a beta of 1.09. The company’s 50-day moving average price is $159.40 and its 200 day moving average price is $170.14. The company has a current ratio of 4.63, a quick ratio of 4.48 and a debt-to-equity ratio of 4.25.

iRhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.27. The company had revenue of $208.89 million for the quarter, compared to the consensus estimate of $202.61 million. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The company’s revenue for the quarter was up 27.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. On average, research analysts expect that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on IRTC shares. Freedom Capital upgraded iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. Evercore raised shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $194.00 to $210.00 in a research note on Monday, January 5th. Robert W. Baird dropped their price target on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday, February 20th. Morgan Stanley restated an “overweight” rating on shares of iRhythm Technologies in a report on Monday, January 12th. Finally, Canaccord Genuity Group lowered their price objective on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, iRhythm Technologies has an average rating of “Moderate Buy” and an average price target of $211.62.

Insider Activity

In other news, EVP Mervin Smith sold 1,352 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $173,650.88. Following the completion of the sale, the executive vice president owned 25,612 shares in the company, valued at approximately $3,289,605.28. The trade was a 5.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chad Patterson sold 4,444 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $128.44, for a total value of $570,787.36. Following the completion of the sale, the insider owned 58,164 shares of the company’s stock, valued at approximately $7,470,584.16. This represents a 7.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 94,509 shares of company stock valued at $12,734,195 in the last 90 days. 0.68% of the stock is owned by corporate insiders.

Key iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Company guidance: iRhythm updated FY‑2026 revenue guidance to $870.0M–$880.0M, noticeably above the consensus (~$817.3M). Higher top‑line guidance is a positive signal for growth and revenue cadence even though EPS guidance was not specified in the release.
• Neutral Sentiment: Analyst/market note: Coverage is shifting as targets are being reset while management’s guidance holds — a thematic piece that explains why price targets and sentiment may be changing even with stronger revenue guidance. How The iRhythm Holdings (IRTC) Story Is Shifting As Targets Reset And Guidance Holds
• Negative Sentiment: Insider selling: Multiple senior execs sold shares on March 2 — including the CAO, several EVPs and other insiders — totaling ~17,826 shares for roughly $2.29M in proceeds (average price ≈ $128.44). Each reported a mid-single-digit percentage reduction in their holdings; insiders still retain substantial stakes but the clustered selling can be perceived negatively by the market. Representative SEC filing: Insider Form 4

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.